Lamivudine

CHEMBL141 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
229.3 g/mol
LogP
-0.9
Phase
4

An antiretroviral nucleoside reverse transcriptase inhibitor used to treat HIV infection and chronic hepatitis B. It works by blocking the reverse transcriptase enzyme that HIV needs to replicate.

Peso Molecular

229,2600 g/mol

LogP

-0,90

TPSA

113,00 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Mecanismo de Ação

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1

InChI

InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

Molecular Formula

C8H11N3O3S

HBD / HBA

2 / 4

Ligações Rotacionáveis

2

Átomos Pesados

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An antiretroviral nucleoside reverse transcriptase inhibitor used to treat HIV infection and chronic hepatitis B. It works by blocking the reverse transcriptase enzyme that HIV needs to replicate.

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Yes, Lamivudine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL141. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 60825. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.